Moneylife » Investing » Companies & Sectors » Sex sells—in drugs too
Sex sells—in drugs too
Revital and I-pill are the best-selling drugs dislodging perennial favourites, cough syrups and vitamins. Pre-sex and post-sex drugs of Ranbaxy and Cipla are selling at a scorching pace
For years, cough syrups and vitamins used to dominate the list of best-selling drugs in India. But now, for the first time in India, a sex stimulant drug has become the largest selling drug in India. Revital, an over the counter drug from Ranbaxy has dislodged Corex (Pfizer) and Phensedyl (Nicholas Piramal) and is ranked as the largest selling drug in India. Revital, a combination of ginseng, vitamins and minerals, from Ranbaxy had sales of Rs66 crore during seven months to July 2009 and growing by healthy 25%. Given this growth, it is likely to cross Rs125-Rs130 crore this year and will create a huge lead in the pecking order of top Indian drugs. A combination of social and economic reasons has pushed the sales of Revital to a new high: higher disposable income, changing lifestyles and increased advertising and promotion. Ranbaxy has spent heavily on advertisements that turned this product into the highest selling drug.
It is not the only the pre-sex drug for men that is hot. The after-sex drug for females has also beaten cough syrups and vitamins. I-pill, a drug from Cipla, used for protection against pregnancy, recorded huge growth and was the second-largest selling drug. Its annual sales are expected to be around Rs80 crore-Rs90 crore. The interesting thing about I–pill is that it is expensive and has even then recorded such massive revenues. This drug costs Rs75 a tablet but obviously demand is huge and price inelastic. Thanks to massive advertisements, I-pill is flying off the shelves. According to industry sources, Cipla has spent Rs20 crore on advertisements for this drug.
It is the advertising that may have done the trick for both Ranbaxy and Cipla. After all, the prescription drugs and Indian equivalent to Viagra (sildenafil citrate) like Kamagra from Ajanta Pharma, Caverta from Ranbaxy, Manforce from Mankind, Penegra from Zydus Cadilla and Suhagra from Cipla are nowhere near the top. Only OTC products can be advertised. Those companies selling prescription drugs cannot. The two companies are also spending hugely on media and public relations.
- Dhruv Rathi news@moneylife.in
More in Moneylife
Banks Vs Depositors +4558 views
TODAY'S TOP STORIES
Post your Comment
| Alert me when new comment is posted on this article | |
| Please read our Moderation Policy and Terms of Use before posting | |
VIDEOS
Moneylife Foundation event on decoding the realty regulator
LATEST COMMENT
I am akashdeep sandhu. I have recently bought flexi smart insurance policy. My yearly premium is ..
akashdeep sandhu
MORE
RIL’s KG-D6 has 80% less reserves than estimated, says Niko
Warburg Pincus buys Future Capital Holdings stake for Rs560 crore
Join 22, 000 Others
Membership Benefits
- Daily & Weekly newsletters
- Access to www.moneylife.in to comment, create alerts
- Your own profile in Moneylife.in
- All special mailers
- Basic membership to MSSN, our new initiative
- Free ebooks
- Invitation to events
- Invitation to round-table meets
- Access to Insurance helpline
- Access to counselling sessions
- Access to Reading room in Mumbai
|
|
|
|||||||||||||||||||||||
|
Take advantage of all our features and functionality exclusively designed for Moneylife.in members. Registration gives you easy access to - Moneylife Newsletters - Exclusive News - Special Features - Membership to Moneylife Foundation - Other Value adds And the registration to this website is completely free. Go ahead and submit this form to create your new profile. |
Tell us about yourself
I have read and agreed to the Terms & Conditions | |||||||||||||||||||
- Banks Vs Depositors
- FIR against godman Brahmrishi Kumarswami
- FIPB defers decision on Jet-Etihad deal; Telenor gets go-ahead
- WPI-based Inflation eases to 4.7% in May
- I-T dept issues Rs816 crore demand notice on Wipro
- Government rectifies IIP data to 2.2% within 24 hours
- When Narayana Murthy walked the talk on Good Governance
- Naxals attack Dhanbad-Patna train, kills RPF jawan
- SEBI seeks details of Infosys board meeting of 1st June
- Amway India chief, two others arrested under PCMCS Act. What about other MLMs?
- TDS on bank deposits: RBI’s advice to acknowledge 15-G/15-H is only half a step
- Corporate Governance: Convenience Rules with Infy Too
- Credit Sudhaar asking Rs16,000 a year for restoring 'credit'?
- Governance Deficit in Infosys?
- “Banks should not be selling third-party products,” RBI deputy governor
- Someone knew Narayana Murthy is coming back and traded on it
- Voila! A demand draft is bounced!
- Many messy reasons why people prefer gold. Can the FM remove them?
- HDFC Bank pitches toxic product to NRIs
- Suicides: Thousands of helpless men are victimized every year, says SIFF
- Mango: Our Super Functional Food
- When Narayana Murthy walked the talk on Good Governance
- Corporate Governance: Convenience Rules with Infy Too
- Exclusive: Here is the Real Estate Bill, kept hidden from public
- Bank problems? You can file an online complaint now
What's your say?
| Yes | |||||||
| No | |||||||
| Can't Say | |||||||
|
What you said
Thanks for casting your votes! View Previous Polls
| Name: |
|
| Email: |
|
| Phone: |
|
| Catagory | |
| Message: |
|
| Enter Code: |
|




























